Sellier Pierre O, Schnepf Nathalie, Amarsy Rishma, Maylin Sarah, Lopes Amanda, Mazeron Marie-Christine, Flateau Clara, Morgand Marjolaine, Ciraru-Vigneron Nicole, Berthe Aurore, Simoneau Guy, Evans John, Souak Safia, Matheron Sophie, Benifla Jean-Louis, Simon François, Bergmann Jean-François
aDepartment of Internal Medicine A bDepartment of Virology cDepartment of Microbiology dDepartment of Obstetrics ePharmacy, AP-HP, Saint-Louis-Lariboisière Hospital fInfectious Diseases Department, AP-HP, Bichat - Claude Bernard Hospital, HUPNVS; Paris-Diderot, Sorbonne Paris-Cité University, Paris, France.
Eur J Gastroenterol Hepatol. 2016 Mar;28(3):328-32. doi: 10.1097/MEG.0000000000000559.
We assessed hepatitis B virus (HBV) status in children born to HIV/HBV coinfected women with large access to antiretroviral therapy.
All HIV/HBV coinfected pregnant women from 01 January 2000 to 01 January 2012 were included in the retrospective study (NCT02044068). Antiretroviral therapy during pregnancy and injection of HBV immunoglobulin/vaccine to newborns was recorded. We assessed HBV status of children aged at least 2 years.
Twenty-one women (35 children) were studied. Twenty-six children (74%) had HBsAb: 22 had received immunoglobulin and 24 had received a complete vaccine (with immunoglobulin in 21 cases); their mothers had been administered lamivudine or tenofovir/emtricitabine during eight and nine pregnancies, respectively. Eight children (23%) were negative for HBsAg, HBsAb, and HBcAb: four (11.5%) had received immunoglobulin and a complete vaccine; in two children, it was not known whether they had received an immunoglobulin injection; in one child, the vaccine was incomplete; and in the last one, it was not known whether he had received immunoglobulin/vaccine. Their mothers had been administered lamivudine or tenofovir/emtricitabine during five and two pregnancies, respectively. No infant has chronic HBV infection (HBsAg) after prenatal mothers' antiretroviral therapy combined with a complete postnatal HBV protection. One child had HBcAb and HBsAb: it was not known whether she had received an immunoglobulin injection; the vaccine was incomplete. The mother had been administered lamivudine during the last trimester of pregnancy.
Antiretroviral therapy in HBV/HIV coinfected women following current national HBV guidelines may prevent mother-to-child-transmission of HBV. Negativity of surrogate markers of vaccine-induced protection is frequent; large studies on long-term protection are needed.
我们评估了有大量机会接受抗逆转录病毒治疗的HIV/HBV合并感染女性所生儿童的乙肝病毒（HBV）感染状况。
2000年1月1日至2012年1月1日期间所有HIV/HBV合并感染的孕妇被纳入这项回顾性研究（NCT02044068）。记录孕期的抗逆转录病毒治疗情况以及给新生儿注射乙肝免疫球蛋白/疫苗的情况。我们评估了至少2岁儿童的HBV感染状况。
研究了21名女性（35名儿童）。26名儿童（74%）有乙肝表面抗体（HBsAb）：22名接受了免疫球蛋白注射，24名接受了全程疫苗接种（21例同时接受了免疫球蛋白注射）；她们的母亲在8次和9次妊娠期间分别接受了拉米夫定或替诺福韦/恩曲他滨治疗。8名儿童（23%）的乙肝表面抗原（HBsAg）、乙肝表面抗体和乙肝核心抗体（HBcAb）均为阴性：4名（11.5%）接受了免疫球蛋白注射和全程疫苗接种；2名儿童不清楚是否接受了免疫球蛋白注射；1名儿童疫苗接种不完整；最后1名儿童不清楚是否接受了免疫球蛋白/疫苗。她们的母亲在5次和2次妊娠期间分别接受了拉米夫定或替诺福韦/恩曲他滨治疗。在产前母亲接受抗逆转录病毒治疗并给予产后全程HBV保护后，没有婴儿发生慢性HBV感染（HBsAg阳性）。1名儿童有乙肝核心抗体和乙肝表面抗体：不清楚她是否接受了免疫球蛋白注射；疫苗接种不完整。母亲在妊娠晚期接受了拉米夫定治疗。
按照当前国家HBV指南对HBV/HIV合并感染女性进行抗逆转录病毒治疗可能预防HBV母婴传播。疫苗诱导保护的替代标志物阴性很常见；需要开展关于长期保护的大型研究。
